Viatris Inc. (VTRS) News
Filter VTRS News Items
VTRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTRS News Highlights
- VTRS's 30 day story count now stands at 20.
- Over the past 21 days, the trend for VTRS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- TOP, DRUG and BEAT are the most mentioned tickers in articles about VTRS.
Latest VTRS News From Around the Web
Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Viatris Partners With Comfort Cases to Support Youth in U.S. Foster CareCommunity Activity Part of Company's Impact Week Anniversary CelebrationPITTSBURGH, PA / ACCESSWIRE / November 21, 2023 / Viatris (NASDAQ:VTRS), a global healthcare company, today announced that it has packed 1,000 backpacks in partnership with Comfort ... |
Viatris Inc's Dividend AnalysisViatris Inc (NASDAQ:VTRS) recently announced a dividend of $0.12 per share, payable on 2023-12-15, with the ex-dividend date set for 2023-11-22. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Viatris Inc's dividend performance and assess its sustainability. |
7 Low P/E Stocks Poised to ReboundEach of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves. |
Top 30 Lowest P/E Ratios of the S&P 500In this article, we will take a look at the top 30 lowest P/E ratios of the S&P 500. To see more such companies, go directly to Top 5 Lowest P/E Ratios of the S&P 500. In its 2024 stock market outlook report, Goldman Sachs claimed that the hard part of the Fed’s battle against […] |
Why the Cheapest Stock in the S&P 500 Is No BargainViatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has been falling ever since the deal closed. |
Viatris to Participate in the Jefferies London Healthcare ConferenceViatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023. Chief Executive Officer Scott A. Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will represent the Company in a fireside chat scheduled at 4:30 a.m. ET / 9:30 a.m. GMT. |
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive results from the YUPELRI® (revefenacin) Phase III placebo-controlled clinical trial conducted in China assessing the efficacy and safety of YUPELRI, a once-daily nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with COPD. Top-line results showed that YUPELRI met its primary efficacy endpoint demonstrating a statistically sign |
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
Top 20 Drug Companies in the US by RevenueIn this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical […] |
The Viatris Inc (VTRS) Company: A Short SWOT AnalysisDecoding Viatris Inc (VTRS): A Strategic SWOT Insight |